$233,588,020

Department of Health and Human Services·National Institutes of Health

ACTION DATE2026-03-26·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75N91020F00039_7529_75N91019D00024_7529

Award description

NIAID COVID-19 ACTIV3

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Supports NIAID's COVID-19 ACTIV3 research program through Leidos Biomedical Research to accelerate therapeutic and vaccine development.

Sub-sectors

vaccine-developmentcovid-19-researchnih-research-grant

Why this matters

ACTIV3 is a critical public-private partnership accelerating COVID-19 treatment and vaccine candidates during pandemic response.

Supply-chain signal

Drives demand for clinical trial infrastructure, manufacturing scale-up for therapeutic candidates, and bioanalytical testing services.

U.S.–China competition angle

U.S. investment in domestic COVID-19 therapeutic R&D counters reliance on foreign pharmaceutical supply chains and advances pandemic preparedness.

Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002260.

Period of performance

Start

2020-09-02

End

2029-09-29

Status

activein 1232 days

Recipient

Other awards from this recipient

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75N91020F00039_7529_75N91019D00024_7529.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.